Gilead, Merck Spar Over Hepatitis C $1,000-Pill RoyaltiesBy
Merck demands $3 billion in royalties to license two patents
Jury in California must decide whether Merck patents are valid
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.